Histone deacetylases (HDACs) have been identified as therapeutic targets due to regulatory function in DNA structure and organization. We have analyzed the role of the LBH589, a novel pan inhibitor of
The G-protein–coupled estrogen receptor (GPER) mediates non-genomic action of estrogen. Due to its differential expression in some tumors as compared to the original healthy tissues, the GPER has been
CD13 inhibitor effects on acute monocytic leukemia cell-lines (THP-1). We also compare the combination with proteasome inhibitors (Bortezomib). The experiment compared the effects of inhibiting CD13,
